Rating Change
Canaccord Genuity reiterated its Buy rating on Bioventus Inc. (NASDAQ:BVS) on August 17, 2026.
reiterateNASDAQ:BVS
Canaccord Genuity Reiterates Buy Rating on Bioventus Inc. (BVS)
Canaccord Genuity reiterated its Buy rating on Bioventus Inc. (NASDAQ:BVS) on August 17, 2026.
At publication ·
What changed
Bioventus Inc. (NASDAQ:BVS) · reiterate
- Firm
- Canaccord Genuity
- Rating
- Buy to Buy
- Price at event
- $13.88
- Market capitalization
- $495.9M
At a glance
Key takeaways
- Canaccord Genuity reiterated a Buy rating on Bioventus Inc. (BVS) on August 17, 2026, with the stock trading at $13.88 and a market capitalization of $495.9 million.
Market Context
Bioventus Inc. operates in the Healthcare sector. The stock currently trades at $13.88 with a market capitalization of $495.9M. The stock has gained 89.4% over the past 52 weeks.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bioventus Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Bioventus Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 17, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jun 30, 2026 | Barrington Research | Outperform | N/A |
| Jun 16, 2026 | Canaccord Genuity | Buy | N/A |
| May 22, 2026 | Barrington Research | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View BVS Stock Page
Frequently Asked Questions
What does the Buy rating mean for BVS?
A rating of Buy from Canaccord Genuity reflects the analyst's outlook on Bioventus Inc. (NASDAQ:BVS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BVS forecast page.
